Physician profile
Corinne L Griffith
NPI 1285632166
$10,750.88
in general payments reported to CMS, 2019-2025
47 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,031 · 2020: $1,332 · 2021: $1,932 · 2022: $1,850 · 2023: $1,678 · 2024: $1,709 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,421 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,421.11 |
| Education | $184.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,834.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,026.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $830.44 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $802.52 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $784.31 | 2019-2025 | |
| Amgen INC. | $572.02 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $501.02 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $489.65 | 2019-2025 | Jardiance, Synjardy |
| Arbor Pharmaceuticals, INC. | $358.42 | 2019-2022 | |
| Astellas Pharma US INC | $353.94 | 2022-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $345.58 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $329.52 | 2019-2025 | Zoryve |
| Glaxosmithkline, LLC. | $326.03 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $272.39 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $192.73 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $190.27 | 2021-2025 | Proclaim, Lamitrode, Eterna |
| Amarin Pharma, INC. | $174.65 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $119.51 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $110.34 | 2022 | |
| Daiichi Sankyo INC. | $95.51 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $95.00 | 2020-2022 | |
| Horizon Therapeutics Plc | $76.79 | 2022-2023 | Krystexxa |
| Exact Sciences Corporation | $62.55 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medtronic, INC. | $54.33 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Eisai INC. | $53.98 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.40 | 2019-2023 | Xifaxan, Trulance |
| Boston Scientific Corporation | $50.34 | 2022 | |
| Idorsia Pharmaceuticals US INC | $46.31 | 2022-2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $44.46 | 2021 | |
| Allergan, INC. | $43.48 | 2020 | |
| Azurity Pharmaceuticals, INC. | $43.06 | 2023 | Edarbi |
| Organogenesis INC. | $42.81 | 2022 | |
| Viiv Healthcare Company | $39.97 | 2025 | Apretude |
| Sanofi Pasteur INC. | $38.96 | 2025 | |
| Seqirus USA INC | $38.21 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $32.51 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $30.70 | 2020-2025 | Contrave |
| Takeda Pharmaceuticals U.S.A., INC. | $28.91 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $25.29 | 2022 | |
| Dexcom, INC. | $24.81 | 2023 | Dexcom G6 Transmitter |
| Abiomed | $23.26 | 2025 | |
| Sonex Health, INC. | $19.99 | 2025 | Sx-One Microknife |
| Vbi Vaccine (Delaware) INC. | $18.72 | 2023 | Prehevbrio |
| Insulet Corporation | $15.26 | 2025 | Omnipod |
| Bausch Health US, LLC | $15.04 | 2019 | |
| Medicure Pharma INC. | $12.16 | 2019 | |
| Lucid Diagnostics INC. | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corinne Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.